Invention Grant
- Patent Title: P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
-
Application No.: US16166031Application Date: 2018-10-19
-
Publication No.: US10342786B2Publication Date: 2019-07-09
- Inventor: Angela Marie Cacace , Luis Gustavo Alejandro Rojas Soto , Lorin A. Thompson, III , Owen Brendan Wallace , Lucienne V. Ronco , Ning Shen , Alan Scott Robertson , Aaron Nakwon Chang
- Applicant: Fulcrum Therapeutics, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Fulcrum Therapeutics, Inc.
- Current Assignee: Fulcrum Therapeutics, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Cooley LLP
- Agent J. Dean Farmer; Ashley M. Dreis
- Main IPC: A61K31/455
- IPC: A61K31/455 ; A61K31/4418 ; A61K45/06 ; A61P21/00 ; C12Q1/686 ; C12Q1/6827 ; A61K9/00
Abstract:
The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
Public/Granted literature
- US20190105311A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Public/Granted day:2019-04-11
Information query
IPC分类:
